Key findings• This study identified paravalvular leak (PVL) in 8.1% of surgical aortic valve replacement (SAVR) cases, with the majority of cases ...

Anteris Technologies Global Corp.’s AVR share price has dipped by 8.54%, which has investors questioning if this is right ...

Trinity was one of the early sites in the United States to be involved in clinical trials for the procedure. By the time it was approved by the FDA in 2021, more than 100 Quad-Cities patients had ...

From genetic risks to inflammation markers, uncover the latest insights in cardiovascular prevention that every primary care ...

Low LDL cholesterol was associated with an increased risk of bleeding in patients receiving anticoagulation for venous ...

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

For patients with asymptomatic severe aortic stenosis, transcatheter aortic valve replacement was superior to clinical ...

This is the summary of “Long-term outcome of bail-out ViV-TAVI at index procedure,” published in the April 2025 issue of ...

The FDA has approved the SAPIEN 3 platform, a TAVR therapy, for patients with severe aortic stenosis without symptoms.

In January 2025, TD Cowen, Barclays and Cantor, the Underwriters to the December 2024 US IPO, partially exercised the green shoe option granted by Anteris. This green shoe option was in respect of ...

Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to ...

Simulations using post-TAVR CT imaging show that redo-TAV is more feasible in patients with bicuspid aortic valves compared to tricuspid aortic valves, according to new research published in JACC: ...